Search
WP-1301
go.drugbank.com/drugs/DB17702ExperimentalIt binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]
Abetimus
go.drugbank.com/drugs/DB06662InvestigationalAbetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.
Pelitinib
go.drugbank.com/drugs/DB05524InvestigationalPelitinib (EKB-569) is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor (EGFR) that is being developed as an anticancer agent.
Asvasiran
go.drugbank.com/drugs/DB05638InvestigationalAsvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Staurosporine
go.drugbank.com/drugs/DB02010ExperimentalAn indolocarbazole that is a potent protein kinase C inhibitor which enhances cAMP-mediated responses in human neuroblastoma cells. (Biochem Biophys Res Commun 1995;214(3):1114-20)
Categories: P-glycoprotein inhibitorsATG002
go.drugbank.com/drugs/DB05068InvestigationalATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors,...
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalAbemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesHyaluronidase (human recombinant)
go.drugbank.com/drugs/DB06205ApprovedInvestigational[A4033] Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents.
Trabectedin
go.drugbank.com/drugs/DB05109ApprovedInvestigationalFood and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesDipyrithione
go.drugbank.com/drugs/DB11327Approved[A32829] Interestingly, dipyrithione has been studied and shown to have cytotoxic and potent broad-spectrum antitumor activity, which suggests a potential basis for an anticancer drug development.